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Abstract Retinoic acid receptor-related orphan receptor K
(RORK) is a member of the nuclear receptor superfamily. Using
RT-PCR, RORK mRNA was identified in human aortic smooth
muscle cells (hASMC), endothelial cells (EC), as well as in
human mammary arteries and atherosclerotic plaques. We found
a predominant expression of RORK1 in hASMC, and RORK4 in
EC. RORK2 and RORK3 were not detected. In arteries, RORK4
was predominant compared with RORK1. In atherosclerotic
plaques, RORK expression was significantly decreased. In
hASMC stimulated with cytokines, RORK expression was
increased by 2.5-fold. RORK mRNA was also significantly
increased (V2-fold) in hASMC and EC cultured under
hypoxia. ß 2002 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
RORK (retinoic acid receptor related orphan receptor K) is
a member of the nuclear hormone-receptor superfamily [1]. Its
primary sequence associates it with the class of retinoic acid
receptors [2]. The characteristic structure of the nuclear recep-
tor comprises a binding domain for the ligand (LBD), another
one for the DNA (DBD), a hinge region linking both of them,
and a ¢xation site for a modulator on the N-terminal region.
The alternative splicing of the gene gives four isoforms of
RORK, di¡ering only in the modulator site [2]. This speci¢city
enables each isoform of RORK to recognize a particular re-
sponsive element, though their DBDs are identical [3].
A spontaneous mutation consisting of a 122 bp deletion in
the LBD in the RORK gene has been identi¢ed in mice [1].
The homozygous mutant mouse (sg/sg) shows cerebellar atax-
ia and neurodegeneration [4,5], and exhibits immune abnor-
malities [6]. We previously reported that the homozygous sg/
sg mutant mouse fed a high-fat diet shows increased athero-
sclerotic lesions compared with the wild type C57BL/6 mouse
[7], suggesting an important role of the nuclear receptor
RORK in atherogenesis. Recently, we found increased ische-
mia-induced angiogenesis in sg/sg mice [8]. RORK has been
reported to be expressed in human aortic smooth muscle cells
(hASMC) [9], but little is known regarding its regulation in
endothelial (EC) and smooth muscle cells (SMC). We there-
fore studied the expression of RORK isoforms in human EC
and SMC, as well as in human arteries, and we investigated
the regulation of RORK by cytokines and hypoxia. Our re-
sults show a constitutive RORK mRNA expression in
hASMC and EC, as well as in human mammary arteries
and atherosclerotic plaques. We found a predominant expres-
sion of RORK1 in hASMC and RORK4 in EC, while no
expression of RORK2 or RORK3 mRNA were detected. In
normal arteries, RORK4 was predominant compared with
RORK1, but RORK mRNA expression was signi¢cantly de-
creased in atherosclerotic lesions.
In both hASMC and EC, we found that RORK was pos-
itively regulated by in£ammatory cytokines.
2. Materials and methods
2.1. Cells
2.1.1. hASMC. hASMC from Clonetics (San Diego, CA, USA)
were obtained from two donors. Cells were used between passages
4 and 8 and were characterized by morphological criteria and smooth
muscle K-actin expression. hASMC were grown in culture medium
supplemented with fetal calf serum (FCS; 5%), insulin (5 Wg/ml),
recombinant human basic ¢broblast growth factor (FGF; 2 ng/ml),
recombinant human epidermal growth factor (EGF; 10 ng/ml), gen-
tamycin (50 Wg/ml) and amphotericin B (50 ng/ml). hASMC were
cultured into 25 cm2 £asks at 3500 cells/cm2 until subcon£uence
was obtained after 7 days in culture.
2.1.2. EC. Human EC were obtained from Promocell (Heidel-
berg, Germany). Cells were used between passages 2 and 4. EC
were grown in culture medium supplemented with FCS (5%), insulin
(5 Wg/ml), recombinant human basic FGF (1 Wg/ml), recombinant
human EGF (0.1 Wg/ml), gentamycin (50 Wg/ml) and amphotericin B
(50 Wg/ml). EC were cultured into 0.2% gelatin-coated 25 cm2 £asks at
5000 cells/cm2 until subcon£uence was obtained after 7 days in cul-
ture.
2.2. Mammary arteries and atherosclerotic plaques
Twenty atherosclerotic plaques removed from patients undergoing
carotid endarterectomy were collected. For controls, four internal
mammary arteries free of atherosclerosis were obtained during coro-
nary bypass surgery. They were rapidly immersed in liquid nitrogen
and stored at 380‡C.
2.3. Cell stimulation
Cells were incubated from 15 min to 72 h in the presence of proin-
£ammatory cytokines tumor necrosis factor K (TNFK ; 10 U/ml), in-
terleukin-1L (IL-1L ; 10 ng/ml), and lipopolysaccharide (LPS; 10 Wg/
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ml), used alone or in combination. Another set of cells was incubated
during 6 h with increasing concentration of IL-1L, from 0 to 10 ng/ml.
In an additional series of experiments, cells were submitted to hypoxia
(95% N2, 5% CO2) for 3 or 6 h.
At the end of each treatment, cells were washed with iced PBS and
frozen at 380‡C.
IL-1L was from Genzyme, Cambridge, MA, USA; LPS from Sig-
ma, Saint Quentin, France; TNFK from RpD, Abingdon, UK.
2.4. Determination of RORK mRNA expression
2.4.1. Total RNA isolation. Total RNA was extracted from cells
and tissues, according to the Trizol reagent protocol (Life Technolo-
gies). The quality of RNA was con¢rmed by ethidium bromide stain-
ing in 1% agarose gel.
2.4.2. RT-PCR protocol. RORK mRNA was ampli¢ed using
primers speci¢c of the common part of the four isoforms of RORK.
First-strand cDNA was performed on 50 ng of total RNA. PCR
conditions were: 39‡C, 60 min; 94‡C, 3 min; 94‡C, 45 s; 55‡C,
1 min, 72‡C, 1 min. The PCR fragments were visualized on a 5%
polyacrylamide gel. Primers and annealing temperatures used were:
RORK, forward primer 5P-GTCAGCAGCTTCTACCTGGAC-3P and
reverse primer 5P-GTGTTGTTCTGAGAGTGAAAGGCACG-3P, 25
cycles, 55‡C; GAPDH forward primer 5P-TGAAGGTCGGTGT-
CAACGGATTTGGC-3P and reverse primer 5P-GTGTTGTTCTGA-
GAGTGAAAGGCACG-3P, 26 cycles, 60‡C.
2.4.3. RT-PCR protocol for RORK isoforms. First-strand cDNA
was performed on 1 Wg of total RNA. PCR conditions were: 37‡C, 60
min; 94‡C, 3 min; 94‡C, 45 s; 60‡C, 1 min, 72‡C, 1 min. After 35
cycles, the PCR fragments were separated on a 0.1% agarose gel, and
then blotted onto a nylon sheet. Speci¢c band was detected with a
radiolabeled probe. Primers and annealing temperatures used were:
RORK1, primer 5P-AAACATGGAGTCAGCTCCG-3P ; RORK2
primer 5P-CTCCAAATACTCCATCAGTGTATCC-3P ; RORK3
primer 5P-CAACTTGAGCACATAAACTGG-3P ; RORK4 primer
5P-GCACCGCGCTTAAATGATGT-3P. For the four isoforms, the
same reverse primer 5P-CATACAAGCTGTCTCTCTGC-3P was used.
Speci¢c probes used for the southern analysis were: RORK1:
5P-CTTCTACCTGGACATACAGC-3P ; RORK2: 5P-GGGATGA-
ACTTTTTGGGATTC-3P ; RORK3: 5P-AGAAGCTCTTCAACCTG-
TAG-3P ; RORK4: 5P-GTGATCGCAGAGATGAAAGC-3P.
2.5. Data analysis
For RT-PCR, percent expression of RORK was expressed relative
to GAPDH mRNA signal. Results are expressed as mean þ S.E.M.
Data were compared by the use of a one-way ANOVA. A P6 0.05
value was considered statistically signi¢cant.
Fig. 1. A: RORK isoforms expression in human vascular cells. B: RORK isoforms expression in human SMC and normal arteries.
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3. Results
We ¢rst veri¢ed whether RORK was expressed in human
vascular cells and arteries. RORK mRNA was found to be
constitutively expressed in both hASMC and EC, as well as in
mammary arteries (Fig. 1). We found a predominant expres-
sion of RORK1 in hASMC, and RORK4 in EC, while no
expression of RORK2 or RORK3 mRNA was detected. In
normal arteries, RORK4 was predominant compared with
RORK1. In human atherosclerotic plaques, RORK mRNA
expression was signi¢cantly decreased (Fig. 2).
As revealed by RT-PCR analysis (Fig. 3, top), incubation
of hASMC for 6 h with increasing concentration of IL-1L
from 0 to 10 ng/ml, dose-dependently increased RORK
mRNA expression. Quanti¢cation (Fig. 3, bottom) showed
that the maximum increase in the RORK mRNA expression
was obtained at 10 ng/ml of IL-1L (150 þ 40%, P6 0.05).
Since RORK is a transcriptional regulator, we studied its
expression kinetics to determine whether it was likely to act
on early or late genes. We stimulated hASMC with IL-1L
(10 ng/ml) for 15 min to 72 h (Fig. 4). RORK mRNA expres-
sion increased signi¢cantly at 2 h, and reached a maximal
level at 6 h (160 þ 53% of control). RORK mRNA expression
remained elevated between 6 and 72 h. In order to evaluate
whether RORK mRNA could be regulated by other cytokines
than IL-1L, we investigated the e¡ects of TNFK, LPS and
IL-1L separately or in conjunction (Fig. 5). Each cytokine
induced a signi¢cant increase (1.5- to 2.5-fold) in RORK
mRNA expression, the most potent activation being by
IL-1L. To evaluate whether RORK was also up-regulated by
cytokines in EC, we incubated EC with IL-1L (10 ng/ml) for
6 h. We found a similar increase in RORK mRNA expression
compared with that observed in hASMC (data not shown).
Finally, to evaluate whether RORK can be stimulated by
hypoxia, hASMC and EC were submitted to hypoxia for 3^6
h. We found that hypoxia induced a rapid and transient in-
crease in RORK mRNA expression. RORK mRNA expres-
sion was increased 3 h after hypoxia (205 þ 18% in SMC and
200 þ 12% in EC), and returned to baseline values after 6 h
(Fig. 6).
Fig. 2. RORK mRNA expression in human normal or atheroscle-
rotic arteries. Atherosclerotic plaques were obtained from carotid
endarterectomia. 50 ng of total RNA was assayed for 25 cycles for
RORK and 26 cycles for GAPDH. Ampli¢ed products are electro-
phoresed onto a 5% polyacrylamide gel.
Fig. 3. Top: Representative RT-PCR of RORK and GAPDH under
stimulation by increased doses of IL-1L. Bottom: Quanti¢cation of
RT-PCR. Results shown are mean þ S.E.M. (n = 4).
Fig. 4. Cells were incubated with the in£ammatory cocktail IL-1L
(10 ng/ml), TNFK (10 U/ml) and LPS (10 Wg/ml) for the indicated
times. 50 ng of total RNA was assayed for 25 and 26 cycles for
RORK and GAPDH, respectively. Ampli¢ed products are electro-
phoresed onto a 5% polyacrylamide gel.
Fig. 5. Regulation of RORK mRNA expression by in£ammatory cy-
tokines in hSMC. hASMC (80% con£uence) were incubated for 6 h
in SmBM medium with IL-1L (10 ng/ml), TNFK (10 U/ml) and
LPS (10 Wg/ml), used alone or within a cocktail. RORK and
GAPDH mRNA levels were measured by RT-PCR. Results shown
are mean þ S.E.M. (n = 5).
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4. Discussion
In the present study, we showed that RORK, a member of
orphan nuclear-receptor family, is expressed in vascular cells
as well as in human arteries. We report for the ¢rst time a
predominant expression of RORK1 in hASMC, and RORK4
in EC, while no expression of RORK2 or RORK3 mRNA was
detected. In normal arteries, RORK4 was predominant com-
pared with RORK1. However, RORK mRNA expression was
signi¢cantly decreased in human atherosclerotic plaques. In
both EC and hASMC, in£ammatory cytokines IL-1L and
TNFK, as well as LPS, increased by about two-fold RORK
mRNA expression. Analysis of the RORK mRNA expression
in response to IL-1L reveals that the time course of the acti-
vation was rapid (W200% after 2^3 h), and sustained (up to
72 h).
Nuclear receptors play an important role in the regulation
of numerous cellular functions. They relieve the di¡erent
physiological e¡ects of their ligands by activating speci¢c ge-
netic programs. The major role of nuclear receptors is to
modulate transcription. They have been especially studied in
embryonic development and in cancer [10^12]. However, little
is known on the expression of nuclear receptors in vascular
cells. Recent studies reported that endothelial cell prolifera-
tion could be modulated by retinoid and steroid hormones via
their nuclear receptors [13,14]. Another nuclear receptor, per-
oxisome proliferator activated receptor-K (PPARK), has been
shown to be expressed in endothelial cells [15] and SMC [16].
Its activation by speci¢c ligands inhibits the in£ammatory
response in these cells [15,16]. A second subtype of PPAR,
PPARQ, might also be expressed in human vascular SMC
and its activation inhibits migration [17].
Several studies have shown that nuclear receptors might
regulate cytokines production. PPAR nuclear-receptor family
has been shown to modulate TNF-K, IL-1L and IL-6 expres-
sion by monocytes [18]. Retinoic acid and vitamin D3 recep-
tors regulate at a transcriptional level the expression of in-
£ammatory cytokine genes [19,20]. However, the e¡ect of
proin£ammatory cytokines on nuclear receptor expression
has been poorly studied. In a previous study, we showed ab-
normalities of IL-1L production in peripheral immune system
of staggerer mice, which carry a deletion in the RORK gene.
In these mutants, LPS-activated peritoneal macrophages over-
express both IL-1L mRNA and protein [21]. Other members
of the RZR/ROR family, such as RORQt, seem to be involved
in the modulation of cytokine expression: RORQt down-reg-
ulates IL-2 production [22].
In the present work, we found that RORK mRNA expres-
sion was enhanced after only 2 h of activation by cytokines,
and remained elevated up to 72 h. This time course of RORK
mRNA expression in the presence of cytokines might suggest
the existence of regulation loops of cytokine production via
RORK. However, in the absence of RORK activator(s) or
inhibitor(s), this hypothesis cannot be tested. Carlberg et al.
proposed that the pineal gland hormone melatonin might be a
natural ligand for RORK [23], but other groups did not con-
¢rm this ¢nding. A thiazolidinedione derivative, CGP 52 608,
has also be reported to be a synthetic ligand of RORK [23].
The development of RORK activator(s) or inhibitor(s) could
allow us to take a long stride in trying to understand how this
new therapeutic target, RORK, could work in atherosclerosis
and other in£ammatory diseases.
While RORK is constitutively expressed in normal vessels, it
is decreased in some of the atherosclerotic plaques analyzed.
Interestingly, the staggerer mice (with RORK deletion) exhibit
exagerated atherosclerosis compared with wild type mice [7].
A RORK-responsive element has been identi¢ed in the pro-
moter of the 5-lipoxygenase gene, which may mediate the
negative regulation of this important in£ammatory gene
[24]. Furthermore, RORK might play a major role in chronic
in£ammation. Peripheral macrophages from sg/sg mice pro-
duce greater amounts of proin£ammatory cytokines, IL-1 and
IL-6, under LPS stimulation [25]. Moreover, RORK1 has re-
cently been reported to interfere negatively with in£ammatory
pathways in smooth muscle cells [9].
There is a striking correlation between in£ammatory gene
induction and susceptibility to fatty streak development in
several inbred mouse strains. As we previously reported,
RORK up-regulates apolipoprotein A-I expression, which ele-
vated plasmatic levels confer protection against atherosclero-
sis [7].
Furthermore, we found a rapid, but transient induction of
RORK mRNA expression by hypoxia in hASMC and EC.
This result gives another trail for a role of RORK in the
vascular physiology and pathology, and is in agreement with
our recent ¢nding that RORK expression is increased in the
mouse ischemic hindlimb following femoral artery ligature [8].
Therefore, RORK might play a role in the control of ische-
mia-induced angiogenesis, as suggested by increased angiogen-
esis in sg/sg mice [8].
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